DEXCOM INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.7B | $4.0B | $3.6B | $2.9B | $2.4B |
| Cost of revenue | $1.9B | $1.6B | $1.3B | $1.0B | $768.0M |
| Gross profit | $2.8B | $2.4B | $2.3B | $1.9B | $1.7B |
| Selling, general & administrative | $1.3B | $1.3B | $1.2B | $1.0B | $810.5M |
| Research and development | $599.1M | $552.4M | $505.8M | $484.2M | $517.1M |
| Operating expenses | $1.9B | $1.8B | $1.7B | $1.5B | $1.4B |
| Operating income | $911.8M | $600.0M | $597.7M | $391.2M | $265.8M |
| Interest expense | $18.3M | $19.0M | $20.3M | $18.6M | $18.8M |
| Pretax income | $1.1B | $709.0M | $710.4M | $390.8M | $256.8M |
| Income tax expense | $252.1M | $132.8M | $168.9M | $49.6M | $39.9M |
| Net income | $836.3M | $576.2M | $541.5M | $341.2M | $216.9M |
| Balance Sheet | |||||
| Cash and equivalents | $917.7M | $606.1M | $566.3M | $642.3M | $1.1B |
| Current assets | $4.0B | $4.3B | $4.4B | $3.7B | $3.7B |
| Total assets | $6.3B | $6.5B | $6.3B | $5.4B | $4.9B |
| Current liabilities | $2.1B | $2.9B | $1.6B | $1.8B | $720.8M |
| Total liabilities | $3.6B | $4.4B | $4.2B | $3.3B | $2.9B |
| Stockholders' equity | $2.7B | $2.1B | $2.1B | $2.1B | $2.0B |
| Cash Flow Statement | |||||
| Cash from operations | $1.4B | $989.5M | $748.5M | $669.5M | $442.5M |
| Depreciation and amortization | $251.8M | $217.7M | $186.0M | $155.9M | $102.0M |
| Stock-based compensation | $159.6M | $170.4M | $150.8M | $126.5M | $113.4M |
| Capital expenditure | $363.5M | $358.8M | $236.6M | $364.8M | $389.2M |
| Free cash flow | $1.1B | $630.7M | $511.9M | $304.7M | $53.3M |
| Share repurchases | $500.0M | $750.0M | $688.7M | $557.7M | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 385.9M · Free float 99.5%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.